Learnings from cross-border biosimilar pricing policies in Europe
Authors:
- 26 March 2024
- journal article
- editorial
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 24 (5) , 585-588
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- A concept for multi-winner tenders for medicinal products with balancing between efficient prices, long-term competition and sustainability of supplyFrontiers in Medicine, 2023
- Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s PerspectiveBioDrugs, 2023
- An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and SpainFrontiers in Medicine, 2023
- Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across EuropeBioDrugs, 2022
- Financial toxicity and cancer treatments: Help from biosimilars – The explanatory case of bevacizumabEuropean Journal of Cancer, 2021
- Streamlined approval of biosimilars: moving on from the confirmatory efficacy trialDrug Discovery Today, 2020
- Evolution of the EU Biosimilar Framework: Past and FutureBioDrugs, 2019
- The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and RituximabAnticancer Research, 2019
- Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countriesExpert Review of Pharmacoeconomics & Outcomes Research, 2018
- Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare CoverageApplied Health Economics and Health Policy, 2018